

Petar Alaupovic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5396164/publications.pdf>

Version: 2024-02-01

19
papers

726
citations

759233

12
h-index

794594

19
g-index

19
all docs

19
docs citations

19
times ranked

521
citing authors

#	ARTICLE	IF	CITATIONS
1	Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D. <i>Journal of Lipid Research</i> , 2018, 59, 872-883.	4.2	8
2	LpA-II:B:C:D:E: a new immunochemically-defined acute phase lipoprotein in humans. <i>Lipids in Health and Disease</i> , 2018, 17, 127.	3.0	2
3	Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2015, 9, 360-367.	1.5	22
4	Influence of Peripheral Artery Disease and Statin Therapy on Apolipoprotein Profiles. <i>International Journal of Vascular Medicine</i> , 2013, 2013, 1-7.	1.0	3
5	Characterization of the Metabolic Syndrome by Apolipoproteins in the Oklahoma Cherokee. <i>Journal of the Cardiometabolic Syndrome</i> , 2008, 3, 193-199.	1.7	11
6	Pistachios beneficially affect multiple lipid and apolipoprotein CVD risk factors. <i>FASEB Journal</i> , 2007, 21, A695.	0.5	1
7	The concept of apolipoprotein-defined lipoprotein families and its clinical significance. <i>Current Atherosclerosis Reports</i> , 2003, 5, 459-467.	4.8	71
8	Alterations in Lipoprotein Composition in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2002, 22, 220-228.	2.3	41
9	Dyslipidemia in Peritoneal Dialysis – Relation to Dialytic Variables. <i>Peritoneal Dialysis International</i> , 2000, 20, 306-314.	2.3	41
10	Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels. <i>Atherosclerosis</i> , 1997, 133, 123-133.	0.8	54
11	Efficacy and Safety of a New Hydroxymethylglutaryl-Coenzyme A Reductase Inhibitor, Atorvastatin, in Patients with Combined Hyperlipidemia: Comparison with Fenofibrate. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 1793-1799.	2.4	66
12	[2] Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins. <i>Methods in Enzymology</i> , 1996, 263, 32-60.	1.0	88
13	Studies on the mechanism of hypertriglyceridemia in Tangier disease. Determination of plasma lipolytic activities, k1 values and apolipoprotein composition of the major lipoprotein density classes. <i>Lipids and Lipid Metabolism</i> , 1987, 920, 9-19.	2.6	53
14	Quantitative determination of human apolipoprotein Cc-III by electroimmunoassay. <i>Lipids and Lipid Metabolism</i> , 1980, 617, 503-513.	2.6	131
15	Isolation and partial characterization of apolipoprotein D and lipoprotein D from baboon plasma. <i>FEBS Letters</i> , 1980, 112, 251-254.	2.8	15
16	Identification of lipoprotein families in a variant of human plasma apolipoprotein A deficiency. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1979, 39, 377-387.	1.2	67
17	Isolation and partial characterization of human erythrocyte membrane NADH: (Acceptor) oxidoreductase. <i>Journal of Supramolecular Structure</i> , 1978, 9, 1-14.	2.3	32
18	A new, simple procedure for the isolation of sialoglycoproteins from human erythrocyte membranes of ABO blood group activities. <i>FEBS Letters</i> , 1976, 65, 159-162.	2.8	8

#	ARTICLE	IF	CITATIONS
19	Effect of estrogen on triacylglycerol metabolism: Inhibition of post-heparin plasma lipoprotein lipase by phosphatidylcholine transfer protein, an estrogen-induced protein. FEBS Letters, 1976, 67, 28-31.	2.8	12